Beta Bionics (NASDAQ:BBNX) Price Target Lowered to $25.00 at Truist Financial

Beta Bionics (NASDAQ:BBNX) had its price objective trimmed by Truist Financial from $37.00 to $25.00 in a research note published on Monday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also recently weighed in on BBNX. Piper Sandler reissued an “overweight” rating and set a $32.00 price objective (up previously from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Stifel Nicolaus reiterated a “buy” rating and set a $31.00 price target (up from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Lake Street Capital boosted their price target on shares of Beta Bionics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Bank of America lowered Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday, January 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $27.18.

Beta Bionics Stock Performance

Shares of NASDAQ BBNX opened at $13.70 on Monday. The stock’s 50-day simple moving average is $25.63 and its 200-day simple moving average is $22.68. The firm has a market capitalization of $603.14 million and a PE ratio of -3.14. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $32.71.

Insider Buying and Selling at Beta Bionics

In related news, insider Mike Mensinger sold 7,800 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.61, for a total transaction of $230,958.00. Following the transaction, the insider owned 82,952 shares of the company’s stock, valued at $2,456,208.72. This trade represents a 8.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the sale, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 32,490 shares of company stock worth $960,835 over the last three months.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Eventide Asset Management LLC raised its stake in shares of Beta Bionics by 0.5% during the third quarter. Eventide Asset Management LLC now owns 4,957,252 shares of the company’s stock worth $98,500,000 after purchasing an additional 24,901 shares during the last quarter. Farallon Capital Management LLC increased its stake in Beta Bionics by 2.6% in the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock valued at $85,718,000 after buying an additional 110,000 shares during the period. Soleus Capital Management L.P. raised its position in Beta Bionics by 12.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after buying an additional 424,817 shares during the last quarter. Sands Capital Alternatives LLC lifted its stake in shares of Beta Bionics by 15.0% in the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock worth $51,981,000 after acquiring an additional 466,331 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after acquiring an additional 1,509,217 shares during the period.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.